Literature DB >> 23312494

Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study.

Bilal Ergül1, Erdem Koçak, Adnan Taş, Levent Filik, Seyfettin Köklü.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23312494     DOI： 10.1016/j.clinre.2012.10.014

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN： 2210-7401            Impact factor:   2.947


× No keyword cloud information.
  4 in total

Review 1.  Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.

Authors:  Ariolana A Dos Santos; Adriana A Carvalho
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

2.  Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori.

Authors:  Meng-Chieh Wu; Yao-Kuang Wang; Chung-Jung Liu; Fang-Jung Yu; Fu-Chen Kuo; Min-Li Liu; Chao-Hung Kuo; Deng-Chyang Wu; Yao-Kang Huang; I-Chen Wu
Journal:  Gastroenterol Res Pract       Date:  2017-07-16       Impact factor: 2.260

Review 3.  Metal complexes of quinolone antibiotics and their applications: an update.

Authors:  Valentina Uivarosi
Journal:  Molecules       Date:  2013-09-11       Impact factor: 4.411

4.  Structural Insights into New Bi(III) Coordination Polymers with Pyridine-2,3-Dicarboxylic Acid: Photoluminescence Properties and Anti-Helicobacter pylori Activity.

Authors:  Mateusz Kowalik; Joanna Masternak; Iwona Łakomska; Katarzyna Kazimierczuk; Anna Zawilak-Pawlik; Piotr Szczepanowski; Oleksiy V Khavryuchenko; Barbara Barszcz
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.